38.27

0.51% -0.26

Royalty Pharma Plc (RPRX)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Royalty Pharma Plc stock is traded at $38.27, with a volume of 378.47K. It is down -0.51% in the last 24 hours and down -2.11% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Previous Close:

$38.53

Open:

$38.52

24h Volume:

378.47K

Relative Volume:

0.09

Market Cap:

$16.35B

Revenue:

$2.31B

Net Income/Loss:

$1.66B

P/E Ratio:

16.66

EPS:

2.297

Net Cash Flow:

$827.02M

1W Performance:

+0.64%

1M Performance:

-2.11%

6M Performance:

+9.22%

1Y Performance:

+53.34%

1-Day Range:

$38.23

$38.66

1-Week Range:

$37.88

$38.93

52-Week Range:

$24.05

$41.24

Royalty Pharma Plc Stock (RPRX) Company Profile

Name

Royalty Pharma Plc

Sector

Healthcare (1132)

Industry

Biotechnology (631)

Phone

(212) 883-0200

Address

110 EAST 59TH STREET, NEW YORK, NY

Employee

Twitter

Next Earnings Date

2025-02-11

Latest SEC Filings

RPRX's Discussions on Twitter

Compare RPRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RPRX Royalty Pharma Plc	38.27	16.46B	2.31B	1.66B	827.02M	2.297
VRTX Vertex Pharmaceuticals Inc	456.42	115.62B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	745.21	79.10B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	850.79	52.39B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.72	51.72B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	201.41	42.00B	447.02M	-1.18B	-906.14M	-6.1812

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-30-25	Initiated	Goldman	Buy
May-16-25	Initiated	Morgan Stanley	Overweight
Jun-03-24	Downgrade	UBS	Buy → Neutral
Jun-14-22	Resumed	UBS	Buy
May-13-22	Initiated	Scotiabank	Sector Outperform
Apr-27-22	Initiated	Goldman	Buy
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight
Apr-06-22	Resumed	Morgan Stanley	Overweight
Oct-29-21	Upgrade	Citigroup	Neutral → Buy
Jul-30-21	Initiated	Tigress Financial	Buy
Nov-09-20	Upgrade	UBS	Neutral → Buy
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	BofA Securities	Buy
Jul-13-20	Initiated	Citigroup	Neutral
Jul-13-20	Initiated	Cowen	Outperform
Jul-13-20	Initiated	Goldman	Neutral
Jul-13-20	Initiated	JP Morgan	Neutral
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight
Jul-13-20	Initiated	SunTrust	Buy
Jul-13-20	Initiated	UBS	Neutral

View All

Royalty Pharma Plc Stock (RPRX) Latest News

08:55 AM

Royalty Pharma stock rises after acquiring cancer drug royalties - Investing.com India

08:55 AM

08:32 AM

Royalty Pharma Acquires Royalty Interest in Nuvalent's Potential Lung Cancer Therapies - marketscreener.com

08:32 AM

07:39 AM

Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million - The Manila Times

07:39 AM

07:32 AM

Royalty Pharma acquires royalty interest in cancer drugs for $315 million - Investing.com

07:32 AM

07:21 AM

Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million - Quiver Quantitative

07:21 AM

07:17 AM

Royalty Pharma acquires drug royalty rights for up to $315 million - StreetInsider

07:17 AM

07:15 AM

Royalty Pharma (Nasdaq: RPRX) buys Nuvalent NSCLC royalties for up to $315M - Stock Titan

07:15 AM

Dec 14, 2025

Squarepoint Ops LLC Makes New $9.85 Million Investment in Royalty Pharma PLC $RPRX - MarketBeat

Dec 14, 2025

Dec 13, 2025

Eventide Asset Management LLC Buys 41,830 Shares of Royalty Pharma PLC $RPRX - MarketBeat

Dec 13, 2025

Adage Capital Partners GP L.L.C. Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat

Dec 13, 2025

Dec 12, 2025

Main Street Financial Solutions LLC Buys 31,844 Shares of Royalty Pharma PLC $RPRX - MarketBeat

Dec 12, 2025

Dec 11, 2025

TD Cowen raises Royalty Pharma stock price target on growth outlook By Investing.com - Investing.com South Africa

Dec 11, 2025

Precision Trading with Royalty Pharma Plc (RPRX) Risk Zones - news.stocktradersdaily.com

Dec 11, 2025

TD Cowen Forecasts Strong Price Appreciation for Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat

Dec 11, 2025

RPRX: TD Cowen Raises Price Target for Royalty Pharma | RPRX Sto - GuruFocus

Dec 11, 2025

TD Cowen raises Royalty Pharma stock price target on growth outlook - Investing.com Nigeria

Dec 11, 2025

Royalty Pharma (RPRX) PT Raised at TD Cowen; 'Best Ideas 2026: Unique Business' - StreetInsider

Dec 11, 2025

Dec 10, 2025

First Trust Advisors LP Has $39.78 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat

Dec 10, 2025

California Public Employees Retirement System Sells 268,263 Shares of Royalty Pharma PLC $RPRX - MarketBeat

Dec 10, 2025

Dec 09, 2025

What Royalty Pharma (RPRX)'s Denali Rare-Disease Royalty Deal and Cash Surge Means For Shareholders - Sahm

Dec 07, 2025

Dec 06, 2025

Royalty Pharma (NASDAQ:RPRX) EVP Sells $4,374,700.00 in Stock - MarketBeat

Dec 06, 2025

11% Of This Royalty Pharma Insider's Holdings Were Sold - 富途牛牛

Dec 06, 2025

Dec 05, 2025

Royalty Pharma Insider Sold Shares Worth $4,375,008, According to a Recent SEC Filing - marketscreener.com

Dec 05, 2025

What's Going On With Denali Therapeutics Stock Friday?Denali Therapeutics (NASDAQ:DNLI) - Benzinga

Dec 05, 2025

Royalty Pharma (RPRX): Assessing Valuation After a Strong Multi‑Month Share Price Rally - Sahm

Dec 05, 2025

Denali Enters Into a $275M Funding Deal With Royalty Pharma - Prime Publishers, Inc.

Dec 05, 2025

Is It Too Late to Reassess Royalty Pharma After Its 52% Surge in 2025? - Yahoo Finance

Dec 05, 2025